BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hutmacher C, Neri D. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev 2019;141:67-91. [PMID: 30201522 DOI: 10.1016/j.addr.2018.09.002] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
Number Citing Articles
1 Silver AB, Leonard EK, Gould JR, Spangler JB. Engineered antibody fusion proteins for targeted disease therapy. Trends Pharmacol Sci 2021;42:1064-81. [PMID: 34706833 DOI: 10.1016/j.tips.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Scheller J, Engelowski E, Moll JM, Floss DM. Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Trends in Immunology 2019;40:258-72. [DOI: 10.1016/j.it.2019.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
3 Moghimi SM, Peer D. Reprogramming the lymphocyte axis for advanced immunotherapy. Adv Drug Deliv Rev 2019;141:1-2. [PMID: 31375166 DOI: 10.1016/j.addr.2019.07.001] [Reference Citation Analysis]
4 Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. An engineered 4-1BBL fusion protein with "activity on demand". Proc Natl Acad Sci U S A 2020;117:31780-8. [PMID: 33239441 DOI: 10.1073/pnas.2013615117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Komatsu S, Tago M, Ando Y, Asoh TA, Kikuchi A. Facile preparation of multi-stimuli-responsive degradable hydrogels for protein loading and release. J Control Release 2021;331:1-6. [PMID: 33434598 DOI: 10.1016/j.jconrel.2021.01.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Murer P, Neri D. Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol 2019;52:42-53. [PMID: 30991144 DOI: 10.1016/j.nbt.2019.04.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
7 George R, Gsottberger F, Ammon A, Wendland K, Mellenthin L, Mackensen A, Müller F. Triton X-114 and Amine-Based Wash Strategy Reduces Lipopolysaccharides to FDA Limit and Achieves Purer, More Potent Recombinant Immunotoxin. Bioconjug Chem 2021;32:713-20. [PMID: 33793193 DOI: 10.1021/acs.bioconjchem.1c00013] [Reference Citation Analysis]
8 Schmid AS, Neri D. Advances in antibody engineering for rheumatic diseases. Nat Rev Rheumatol 2019;15:197-207. [PMID: 30814691 DOI: 10.1038/s41584-019-0188-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
9 Hyrenius-wittsten A, Roybal KT. Paving New Roads for CARs. Trends in Cancer 2019;5:583-92. [DOI: 10.1016/j.trecan.2019.09.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
10 Neri D. Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity. Cancer Immunol Res 2019;7:348-54. [PMID: 30824549 DOI: 10.1158/2326-6066.CIR-18-0622] [Cited by in Crossref: 52] [Cited by in F6Publishing: 23] [Article Influence: 26.0] [Reference Citation Analysis]
11 Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies (Basel) 2019;8:E55. [PMID: 31816964 DOI: 10.3390/antib8040055] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
12 Shofolawe-Bakare OT, Stokes LD, Hossain M, Smith AE, Werfel TA. Immunostimulatory biomaterials to boost tumor immunogenicity. Biomater Sci 2020;8:5516-37. [PMID: 33049007 DOI: 10.1039/d0bm01183e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Corti A, Calimeri T, Curnis F, Ferreri AJM. Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α. Pharmaceutics 2022;14:1414. [DOI: 10.3390/pharmaceutics14071414] [Reference Citation Analysis]
14 Zhang J, Zhao X. Administration of fusion cytokines induces tumor regression and systemic antitumor immunity. MedComm (2020) 2021;2:256-68. [PMID: 34766145 DOI: 10.1002/mco2.68] [Reference Citation Analysis]
15 Lim C, Won WR, Moon J, Sim T, Shin Y, Kim JC, Lee ES, Youn YS, Oh KT. Co-delivery of d -(KLAKLAK) 2 peptide and doxorubicin using a pH-sensitive nanocarrier for synergistic anticancer treatment. J Mater Chem B 2019;7:4299-308. [DOI: 10.1039/c9tb00741e] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 [DOI: 10.1101/739987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Schadt S, Hauri S, Lopes F, Edelmann MR, Staack RF, Villaseñor R, Kettenberger H, Roth AB, Schuler F, Richter WF, Funk C. Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges. Drug Metab Dispos 2019;47:1443-56. [DOI: 10.1124/dmd.119.088997] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
18 Puca E, Probst P, Stringhini M, Murer P, Pellegrini G, Cazzamalli S, Hutmacher C, Gouyou B, Wulhfard S, Matasci M, Villa A, Neri D. The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors. Int J Cancer 2020;146:2518-30. [PMID: 31374124 DOI: 10.1002/ijc.32603] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
19 Xue J, Chen K, Hu H, Gopinath SCB. Progress in gene therapy treatments for prostate cancer. Biotechnol Appl Biochem 2021. [PMID: 33988271 DOI: 10.1002/bab.2193] [Reference Citation Analysis]
20 Schmid AS, Neri D. Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation. PLoS One 2019;14:e0219313. [PMID: 31348785 DOI: 10.1371/journal.pone.0219313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Dakhel S, Ongaro T, Gouyou B, Matasci M, Villa A, Neri D, Cazzamalli S. Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade. Oncotarget 2019;10:6678-90. [PMID: 31803362 DOI: 10.18632/oncotarget.27320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Belotti D, Pinessi D, Taraboletti G. Alternative Vascularization Mechanisms in Tumor Resistance to Therapy. Cancers (Basel) 2021;13:1912. [PMID: 33921099 DOI: 10.3390/cancers13081912] [Reference Citation Analysis]
23 Orecchia P, Balza E, Pietra G, Conte R, Bizzarri N, Ferrero S, Mingari MC, Carnemolla B. L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model. Cancers (Basel) 2019;11:E1232. [PMID: 31443604 DOI: 10.3390/cancers11091232] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ziffels B, Stringhini M, Probst P, Fugmann T, Sturm T, Neri D. Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice. Mol Cancer Ther 2019;18:1544-54. [PMID: 31213507 DOI: 10.1158/1535-7163.MCT-18-1301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
25 Wittrup KD, Kaufman HL, Schmidt MM, Irvine DJ. Intratumorally anchored cytokine therapy. Expert Opin Drug Deliv 2022;:1-8. [PMID: 35638290 DOI: 10.1080/17425247.2022.2084070] [Reference Citation Analysis]
26 Mortensen MR, Mock J, Bertolini M, Stringhini M, Catalano M, Neri D. Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors. Oncotarget 2020;11:3972-83. [PMID: 33216834 DOI: 10.18632/oncotarget.27772] [Reference Citation Analysis]
27 Pires IS, Hammond PT, Irvine DJ. Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress. Adv Ther (Weinh) 2021;4:2100035. [PMID: 34734110 DOI: 10.1002/adtp.202100035] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Kim S, Jeong H. Soluble Expression of a Neo2/15-Conjugated Single Chain Fv against PD-L1 in Escherichia coli. CIMB 2022;44:301-8. [DOI: 10.3390/cimb44010022] [Reference Citation Analysis]
29 Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S, Pan L. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 2022;7:39. [PMID: 35132063 DOI: 10.1038/s41392-021-00868-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
30 Graham JC, Hillegass J, Schulze G. Considerations for setting occupational exposure limits for novel pharmaceutical modalities. Regul Toxicol Pharmacol 2020;118:104813. [PMID: 33144077 DOI: 10.1016/j.yrtph.2020.104813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Ye QN, Wang Y, Shen S, Xu CF, Wang J. Biomaterials-Based Delivery of Therapeutic Antibodies for Cancer Therapy. Adv Healthc Mater 2021;10:e2002139. [PMID: 33870637 DOI: 10.1002/adhm.202002139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
32 Bonati L, Tang L. Cytokine engineering for targeted cancer immunotherapy. Curr Opin Chem Biol 2021;62:43-52. [PMID: 33684633 DOI: 10.1016/j.cbpa.2021.01.007] [Reference Citation Analysis]
33 Du Y, Xu J. Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Adv Mater 2021;33:e2103114. [PMID: 34585802 DOI: 10.1002/adma.202103114] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tang F, Tie Y, Wei YQ, Tu CQ, Wei XW. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. Biochim Biophys Acta Rev Cancer 2021;1876:188606. [PMID: 34371128 DOI: 10.1016/j.bbcan.2021.188606] [Reference Citation Analysis]
35 Briquez PS, Hauert S, de Titta A, Gray LT, Alpar AT, Swartz MA, Hubbell JA. Engineering Targeting Materials for Therapeutic Cancer Vaccines. Front Bioeng Biotechnol. 2020;8:19. [PMID: 32117911 DOI: 10.3389/fbioe.2020.00019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
36 Silva AC, Lobo JMS. Cytokines and Growth Factors. Adv Biochem Eng Biotechnol 2020;171:87-113. [PMID: 31384960 DOI: 10.1007/10_2019_105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]